News
TRVI
13.19
+2.85%
0.37
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Trevi Therapeutics (TRVI)
TipRanks · 2d ago
Weekly Report: what happened at TRVI last week (0928-1002)?
Weekly Report · 4d ago
Trevi Therapeutics management to meet with Cantor
TipRanks · 09/29 19:05
Weekly Report: what happened at TRVI last week (0921-0925)?
Weekly Report · 09/28 09:06
Weekly Report: what happened at TRVI last week (0914-0918)?
Weekly Report · 09/21 09:06
Weekly Report: what happened at TRVI last week (0907-0911)?
Weekly Report · 09/14 09:06
Weekly Report: what happened at TRVI last week (0831-0904)?
Weekly Report · 09/07 09:06
Weekly Report: what happened at TRVI last week (0824-0828)?
Weekly Report · 08/31 09:06
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Barchart · 08/26 06:30
Weekly Report: what happened at TRVI last week (0817-0821)?
Weekly Report · 08/24 09:06
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
Seeking Alpha · 08/20 05:19
Weekly Report: what happened at TRVI last week (0810-0814)?
Weekly Report · 08/17 09:06
Trevi Therapeutics Price Target Raised to $28.00/Share From $24.00 by Jones Trading
Dow Jones · 08/14 13:01
Trevi Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 08/14 13:01
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Benzinga · 08/14 12:52
Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position
TipRanks · 08/13 19:35
Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target
TipRanks · 08/11 10:15
Weekly Report: what happened at TRVI last week (0803-0807)?
Weekly Report · 08/10 09:06
Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged
TipRanks · 08/07 21:35
Trevi Therapeutics Price Target Raised to $25.00/Share From $24.00 by Oppenheimer
Dow Jones · 08/07 15:31
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.